High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial

AbstractBackground:Glioblastoma multiforme (GBM) is a rare and deadly disease, with a reported average incidence rate of 3.19 cases per 100,000 inhabitants. Fotemustine, a third-generation nitrosourea with an alanine phosphor carrier that facilitates cellular penetration, has been extensively invest